Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic medicines, today announced financial results for the quarter ended September 30, 2024 and multiple strategic and leadership updates, including the appointment of Kaan Certel, Ph.D., an industry veteran with extensive experience in corporate strategy and business development, as Chief Executive Officer. Dr. Certel succeeds Mahesh Karande as CEO, who has decided to leave Omega for personal reasons. In addition, the Company shared updated clinical data from the Phase 1 MYCHELANGELO™ I clinical trial and a strategic prioritization of its pipeline to focus resources on programs in which the Company believes epigenomic controllers have the potential to demonstrate therapeutic advantages over existing modalities, address significant unmet needs and unlock rapid value creation.

Read more at globenewswire.com